Impact of CYP2D62A, CYP2D64 and CYP3A53 genetic polymorphisms on Bisoprolol peak concentration and clinical response in acute coronary syndrome patients

Aims Acute coronary syndrome (ACS) represents a major cause of death. Bisoprolol is commonly used in the management of ACS. This study aims to investigate the impact of CYP2D6*2A, CYP2D6*4 and CYP3A5*3 genetic polymorphisms on pharmacokinetics and clinical response of bisoprolol in ACS patients. Met...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of clinical pharmacology 2024-10, Vol.90 (10), p.2539-2553
Hauptverfasser:	Okda, Sherouk M., El‐Bassiouny, Noha A., El Amrawy, Ahmed Mahmoud, Salahuddin, Ahmad, Elonsy, Sohila M., Kassem, Amira B.
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute Coronary Syndrome - blood Acute Coronary Syndrome - drug therapy Acute Coronary Syndrome - genetics Adrenergic beta-1 Receptor Antagonists - administration & dosage Adrenergic beta-1 Receptor Antagonists - pharmacokinetics Adrenergic beta-1 Receptor Antagonists - therapeutic use Aged Bisoprolol - pharmacokinetics Bisoprolol - therapeutic use bisoprolol, CYP2D6, CYP3A5, peak concentration, polymorphism Blood Pressure - drug effects Blood Pressure - genetics Cohort Studies Cytochrome P-450 CYP2D6 - genetics Cytochrome P-450 CYP3A - genetics Female Genotype Heart Rate - drug effects Heart Rate - genetics Humans Male Middle Aged Polymorphism, Genetic
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Aims Acute coronary syndrome (ACS) represents a major cause of death. Bisoprolol is commonly used in the management of ACS. This study aims to investigate the impact of CYP2D62A, CYP2D64 and CYP3A53 genetic polymorphisms on pharmacokinetics and clinical response of bisoprolol in ACS patients. Methods This is an open‐label cohort study that included 127 ACS patients and studied the effect of CYP3A53, CYP2D62A and CYP2D64 genotyping using real‐time polymerase chain reaction on steady state bisoprolol plasma peak concentration analysed by high performance liquid chromatography–fluorescence detector. Results Regarding CYP3A5*3, the mean peak bisoprolol concentration for CC, CT and TT genotypes were 4.25 ± 1.20, 3.93 ± 1.10 and 1.79 ± 0.69 ng/mL, respectively (P
ISSN:	0306-5251 1365-2125 1365-2125
DOI:	10.1111/bcp.16134